Markets
Hims & Hers Big Game commercial
A screenshot of Hims & Hers’ 2025 Super Bowl commercial (Sherwood News)

Hims slips after US lawmakers introduce bill cracking down on compounding

Analysts at Citi said that the bill presents a headwind for Hims.

J. Edward Moreno

Hims & Hers slipped on Wednesday after members of Congress introduced a bill that would limit its ability to sell copies of blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.

The bill, “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025,” is sponsored by Rep. Rudy Yakym III and Rep. Andre Carson, both of Indiana, where Lilly is headquartered. The bill would raise the bar for when it is legal to dispense compounded versions of popular weight-loss drugs, an industry that has exploded in the past couple of years.

Analysts at Citi said that the bill presents a headwind for Hims. It would “significantly curtail [Hims’] ability to compound GLP-1s,” the product category where the company has seen the most revenue growth in the past year, the analysts said in a Wednesday morning note.

Under federal law, compounding pharmacies can sell exact copies of a branded medication only when it is in a shortage. Lilly and Novo’s GLP-1s were taken off the Food and Drug Administration’s shortage list earlier this year, meaning compounding pharmacies could only continue selling bespoke versions for individual patients.

Telehealth companies like Hims have continued to market compounded GLP-1s, often referring to them “personalized.” The bill would raise the bar for when that is allowed, requiring a doctor to determine whether a compounded version creates a “significant difference” over the commercially available version sold by drugmakers.

The drugmakers have pushed back on telehealth companies’ claim of “personalization,” arguing that the drugs are mass produced and not made for specific patients like the law intends. Lilly and Novo have taken some of these companies to court, and have for the most part lost. The drugmakers have also urged the FDA to up enforcement, but it shares regulatory responsibility with a patchwork of state regulators.

The SAFE Act may empower the FDA to crack down on compounders, which have been nibbling away at drugmakers’ market share.

Hims did not immediately respond to a request for comment.

More Markets

See all Markets
markets

Report: Boeing could unveil 500-jet order from China during Trump’s visit later this month

Shares of Boeing are up nearly 4% on Friday afternoon, following a Bloomberg report that the company could be close to finalizing a deal to sell 500 planes to China.

The deal was first reported in August and would be one of Boeing’s largest ever.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

According to Bloomberg’s sources, the deal could be officially unveiled when President Trump travels to China at the end of the month. That trip could be delayed given the war in Iran. The deal, sources say, could still fall apart — similar language to when it was first reported on more than six months ago.

Boeing has been on the outside of the Chinese market, in terms of new orders, since 2019 amid escalating US-China trade tensions.

markets

Why software shares are withstanding the war jitters

The outbreak of the war in Iran has clearly rattled investors and created a few clear winners — mostly energy stocks — and losers — consumer staples, airlines, and, well, more or else everything else.

But there is one interesting outlier to that Manichaean market dynamic.

Software shares — often the same companies that the market was giving up for dead just a few weeks ago due to overexpectations of an AI-driven disruption — have been holding up remarkably well.

These companies, including Intuit, ServiceNow, Datadog, Snowflake, IBM, Workday, and Oracle, have actually had a pretty decent run since the war started with a combined US-Israeli attack on Iran last weekend.

A new note from RBC Capital’s Rishi Jaluria suggests this isn’t just a fluke. Looking at the performance of software stocks during periods of geopolitical stress and market volatility over the last 10 and 25 years, his team found that software shares appear fairly well insulated when these broader shocks hit. RBC wrote:

“The defensive nature of SaaS models and the mission-critical nature of many core software systems at the enterprise level (e.g., in the absence of mass layoffs that may create seat-based headwinds, geopolitical uncertainty and/or market volatility typically will not cause an enterprise CIO to consider ripping out their ERP, CRM, Cyber systems, etc.”

I briefly got Jaluria on the phone yesterday, and he explained a bit more about why he thinks investors might see software as a decent place to hide out from the current chaos.

“With everything in the Middle East, you have to think about not just oil and gas input prices but also supply chains,” he said. “With software, you’re not really thinking about that.”

In other words, there is no equivalent of a closure of the Strait of Hormuz that software investors have to worry about.

Others suggested that the near-term profitability of these giant software companies — aside from concerns about potential long-term disruption from AI — may look different in the face of the economic uncertainty that seems to be growing with the war, especially after a sell-off that has left them relatively attractively valued.

Mark Moerdler, who covers software stocks for Bernstein Research, says that while the AI worries are clearly real, software companies continue to be highly productive cash cows.

“Everyone is afraid that AI is a massive disruptor, and all these articles you read talk about AI as massive disruptor or the world is ending or whatever,” he said. “You don’t see it in the fundamental numbers of the companies I cover. They are delivering GAAP profits, free cash flow, and they’re good investment ideas.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.